Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations

[1]  Shitij Kapur,et al.  Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation , 2011, Biological Psychiatry.

[2]  Katsuya Harada,et al.  Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. , 2011, Life sciences.

[3]  Xu-Feng Huang,et al.  Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats , 2011, Behavioural Brain Research.

[4]  J. Frampton.  Olanzapine Long-Acting Injection , 2010, Drugs.

[5]  A. A. Abdul Majeed,et al.  A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia. , 2010, Methods and Findings in Experimental and Clinical Pharmacology.

[6]  E. Poluzzi,et al.  Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara , 2010, European Journal of Clinical Pharmacology.

[7]  Alan A. Wilson,et al.  The Antipsychotics Olanzapine, Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro , 2010, Neuropsychopharmacology.

[8]  W. Hall,et al.  Patterns of Antipsychotic Medication Use in Australia 2002–2007 , 2010, The Australian and New Zealand journal of psychiatry.

[9]  Gary Remington,et al.  From mice to men: What can animal models tell us about the relationship between mental health and physical activity? , 2009 .

[10]  G. Remington,et al.  Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model , 2009, Schizophrenia Research.

[11]  P. Fletcher,et al.  Insulin Resistance and Decreased Glucose-Stimulated Insulin Secretion After Acute Olanzapine Administration , 2008, Journal of clinical psychopharmacology.

[12]  G. Remington,et al.  Insulin resistance following continuous, chronic olanzapine treatment: An animal model , 2008, Schizophrenia Research.

[13]  M. Crismon,et al.  Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997–2002 , 2008, The Annals of pharmacotherapy.

[14]  S. Kapur,et al.  Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. , 2008, The Journal of clinical psychiatry.

[15]  K. Newell,et al.  Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression , 2008, Psychoneuroendocrinology.

[16]  S. L. la Fleur,et al.  Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. , 2008, European journal of pharmacology.

[17]  S. Hiriyanna,et al.  Identification and Characterization of Olanzapine Degradation Products under Oxidative Stress Conditions , 2008 .

[18]  R. Spealman,et al.  Controversies in translational research: drug self-administration , 2008, Psychopharmacology.

[19]  H. Brunner,et al.  Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations. , 2008, Journal of pharmaceutical sciences.

[20]  Tadafumi Kato,et al.  Animal models of bipolar disorder , 2007, Neuroscience & Biobehavioral Reviews.

[21]  R. Luthringer,et al.  Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs , 2007, Journal of psychopharmacology.

[22]  M. Raskind,et al.  Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats , 2007, Neuropsychopharmacology.

[23]  J. Newcomer,et al.  Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. , 2007, The Journal of clinical psychiatry.

[24]  S. Preskorn.  Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future , 2006, Journal of psychopharmacology.

[25]  P. Even,et al.  Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration , 2006, Appetite.

[26]  S. Kapur,et al.  A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. , 2006, The American journal of psychiatry.

[27]  P. Even,et al.  Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection , 2005, Behavioural Brain Research.

[28]  S. Kapur,et al.  Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats , 2005, Schizophrenia Research.

[29]  M. Seager,et al.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder , 2005, Psychopharmacology.

[30]  S. Kapur,et al.  Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats , 2005, Biological Psychiatry.

[31]  Robert M Bilder,et al.  Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.

[32]  S. Kapur,et al.  Differential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats , 2003, Neuropsychopharmacology.

[33]  S. Kapur,et al.  Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[34]  R. Vries,et al.  Lack of Correlation between the Steady‐State Plasma Concentrations of Haloperidol and Risperidone , 2002, Journal of clinical pharmacology.

[35]  G. Remington,et al.  The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? , 2002, Neuroscience & Biobehavioral Reviews.

[36]  G. Bartzokis,et al.  Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. , 2001, The American journal of psychiatry.

[37]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[38]  S. Kapur,et al.  Are Animal Studies of Antipsychotics Appropriately Dosed?: Lessons from the Bedside to the Bench , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[39]  S. Marder,et al.  Pharmacokinetics and tissue distribution of olanzapine in rats , 1999, Biopharmaceutics & drug disposition.

[40]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[41]  O. Olesen,et al.  Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[42]  F. García-Carmona,et al.  Cyclodextrins as Secondary Antioxidants: Synergism with Ascorbic Acid , 1997 .

[43]  C. Halldin,et al.  D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.

[44]  G. Simpson,et al.  Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. , 1990, Journal of clinical psychopharmacology.

[45]  N. Nair,et al.  The Bioavailability and Pharmacokinetics of Oral and Depot Intramuscular Haloperidol in Schizophrenic Patients , 1987, Journal of clinical pharmacology.

[46]  G. Juckel,et al.  Drug Prescription Patterns in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund , 2009, Pharmacopsychiatry.

[47]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[48]  T. S. Harrison,et al.  Long-Acting Risperidone , 2004, CNS drugs.

[49]  S. Kapur,et al.  The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats , 2002, Psychopharmacology.

[50]  S. Kapur,et al.  Elevation of prolactin levels by atypical antipsychotics. , 2002, The American journal of psychiatry.

[51]  T. Gillespie,et al.  Disposition and biotransformation of the antipsychotic agent olanzapine in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[52]  L. Ereshefsky,et al.  Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. , 1990, Psychopharmacology bulletin.